Guardant Health (GH) Q2 2025 Earnings
Reported Jul 30, 2025 at 4:08 PM ET · SEC Source
Q2 25 EPS
$-0.44
BEAT +14.53%
Est. $-0.51
Q2 25 Revenue
$232.1M
BEAT +9.85%
Est. $211.3M
vs S&P Since Q2 25
+256.7%
BEATING MARKET
GH +274.5% vs S&P +17.8%
Market Reaction
Did GH Beat Earnings? Q2 2025 Results
Guardant Health posted a notably strong second quarter, with revenue of $232.09 million climbing 30.9% year over year and handily clearing the $211.28 million consensus estimate by 9.85%, while its loss per share of $0.44 came in well ahead of the $0… Read more Guardant Health posted a notably strong second quarter, with revenue of $232.09 million climbing 30.9% year over year and handily clearing the $211.28 million consensus estimate by 9.85%, while its loss per share of $0.44 came in well ahead of the $0.51 analysts had expected, representing a 14.53% beat. The headline driver was broad commercial momentum across all three business segments, most visibly in Shield, the company's colorectal cancer screening product, which generated $14.81 million from roughly 16,000 tests in just its third full quarter on the market, exceeding management's own expectations. Oncology revenue grew 22% to $158.69 million on a 30% rise in test volumes, while Biopharma and Data expanded 28% to $56.02 million. Non-GAAP gross margin widened to 66% from 60% a year ago. Encouraged by the momentum, Guardant raised its full-year 2025 revenue guidance to $915 million to $925 million, reflecting 24% to 25% annual growth, with Screening revenue guidance climbing to $55 million to $60 million from the prior $40 million to $45 million range.
Key Takeaways
- • Oncology test volume grew 30% year over year to approximately 64,000 tests
- • Guardant360 Tissue average selling price increased to approximately $2,000, achieving 2028 target three years early
- • Guardant360 Liquid year-over-year growth accelerated for the fourth consecutive quarter
- • Increased reimbursement for Oncology tests
- • Higher GuardantINFINITY average selling prices and increased biopharmaceutical service agreements
- • Non-GAAP gross margin expanded to 66% from 60% in the prior year period
- • Shield volume of approximately 16,000 screening tests exceeded expectations
GH YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
GH Revenue by Segment
With YoY comparisons, source: SEC Filings
“Q2 was another exceptional quarter for Guardant and we were able to increase our 2025 revenue guidance yet again. We saw especially strong performance from Guardant360 Liquid, where year-over-year growth accelerated for the fourth consecutive quarter.”
— Helmy Eltoukhy, Q2 2025 Earnings Press Release
GH Earnings Trends
GH vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
GH EPS Trend
Earnings per share: estimate vs actual
GH Revenue Trend
Quarterly revenue: estimate vs actual
GH Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $-0.47 | $-0.45 | +4.98% | $301.7M | +8.10% |
| Q4 25 MISS FY | $-0.47 | $-0.50 | -6.52% | $281.3M | +3.30% |
| FY Full Year | — | $-1.82 | — | $982.0M | — |
| Q3 25 BEAT | $-0.49 | $-0.39 | +20.33% | $265.2M | +11.87% |
| Q2 25 BEAT | $-0.51 | $-0.44 | +14.53% | $232.1M | +9.85% |